{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:07:44Z","timestamp":1791454064352,"version":"4.3.3"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T00:00:00Z","timestamp":1542758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Regeneron Pharmaceuticals"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jjcc.2018.10.004","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T09:26:19Z","timestamp":1543569979000},"page":"218-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON"],"prefix":"10.1016","volume":"73","author":[{"given":"Tamio","family":"Teramoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arihiro","family":"Kiyosue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie T.","family":"Baccara-Dinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Sata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2018.10.004_bib0200","series-title":"Global health estimates for 2000\u20132012: cause-specific mortality","author":"World Health Organization (WHO)","year":"2000"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0205","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(10)62038-7","article-title":"National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants","volume":"377","author":"Farzadfar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0210","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0215","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1253\/circj.67.287","article-title":"Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients","volume":"67","author":"Matsuzawa","year":"2003","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0220","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.amjcard.2006.08.051","article-title":"Safety and efficacy of statins in Asians","volume":"99","author":"Liao","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0225","doi-asserted-by":"crossref","first-page":"e002040","DOI":"10.1136\/bmjopen-2012-002040","article-title":"Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information","volume":"3","author":"Chang","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0230","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/clpt.2010.31","article-title":"Exploring differences in drug doses between Japan and Western countries","volume":"87","author":"Arnold","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0235","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.atherosclerosis.2016.07.001","article-title":"Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: an analysis of more than 33,000 high cardiovascular risk patients in Japan","volume":"251","author":"Teramoto","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0240","first-page":"415","article-title":"Epidemiological studies of cholesterol management by statin treatment in 2012 edition of atherosclerotic cardiovascular disease prevention guidelines","volume":"41","author":"Teramoto","year":"2013","journal-title":"Jpn Pharmacol Ther"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2012.02.001","article-title":"Japan Lipid Guideline Achievement Program I. Cross-sectional survey to assess the status of lipid management in high-risk patients with dyslipidemia: clinical impact of combination therapy with ezetimibe","volume":"73","author":"Teramoto","year":"2012","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0250","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jjcc.2017.02.004","article-title":"Current status of lipid management in acute coronary syndrome","volume":"70","author":"Fujisue","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jjcc.2017.07.002","article-title":"PCSK9 inhibition in the management of familial hypercholesterolemia","volume":"71","author":"Ogura","year":"2018","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0260","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0265","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0270","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0275","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0280","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0285","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0290","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0300","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0305","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","article-title":"Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins \u2013 ODYSSEY JAPAN randomized controlled trial","volume":"80","author":"Teramoto","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0310","first-page":"5","article-title":"Efficacy and safety of alirocumab 150mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II Study","author":"Stroes","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0315","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","volume":"49","author":"Careskey","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0320","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/JAHA.116.003323","article-title":"Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin\/kexin type 9, and alirocumab levels after different lipid-lowering strategies","volume":"5","author":"Rey","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0325","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12944-017-0513-7","article-title":"Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale","volume":"16","author":"Teramoto","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0330","doi-asserted-by":"crossref","first-page":"603","DOI":"10.5551\/jat.15867","article-title":"Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan \u2013 2012","volume":"20","author":"Teramoto","year":"2013","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0335","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia","volume":"303","author":"Scientific Steering Committee on behalf of the Simon Broome Register Group","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0340","unstructured":"World Health Organization. Familial Hypercholesterolemia (FH). Report of a second WHO Consultation; 1998. http:\/\/whqlibdoc.who.int\/hq\/1999\/WHO_HGN_FH_CONS_99.2.pdf?ua=1. [Accessed 14 June 2018]."},{"key":"10.1016\/j.jjcc.2018.10.004_bib0345","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0350","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5551\/jat.36004","article-title":"Lipid management in a Japanese community:attainment rate of target set by the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012","volume":"24","author":"Tada","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0355","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0360","first-page":"635","article-title":"Do Singapore patients require lower doses of statins? The SGH Lipid Clinic experience","volume":"44","author":"Tan","year":"2003","journal-title":"Singap Med J"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0365","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1185\/030079904125004367","article-title":"Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies","volume":"20","author":"Morales","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0370","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-014-1800-0","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States","volume":"71","author":"Birmingham","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0375","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy \u2013 European Atherosclerosis Society Consensus Panel Statement on Assessment Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0380","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2013 the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0385","first-page":"635","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.004_bib0390","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508718302958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508718302958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:00:15Z","timestamp":1760274015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508718302958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0914508718302958"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2018.10.004","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd on behalf of Japanese College of Cardiology.","name":"copyright","label":"Copyright"}]}}